Sandoz Group AG (FRA:D8Y) Defensive Interval Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:D8Y Sandoz Group AG FRA:D8Y
38 GF Score
Price €77.06
GF Value €50.54
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Sandoz Group AG Defensive Interval Ratio?

FRA:D8Y
38GF Score
Sandoz Group AG FRA:D8Y
Defensive Interval Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sandoz Group AG (FRA:D8Y) Overvalued in 2026?

Based on GuruFocus' analysis, Sandoz Group AG stock appears to be overvalued. The current stock price of €77.06 is trading 52.5% above its estimated GF Value™ of €50.54. GuruFocus considers Sandoz Group AG to be Significantly Overvalued.

Key valuation signals for FRA:D8Y:

  • Defensive Interval Ratio:
  • GF Value™: €50.54 vs. price of €77.06 (52.5% above fair value)
  • GF Score™: 38/100 with 3 warning signs

No single metric tells the full story. See the FRA:D8Y stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sandoz Group AG Business Description

Address Centralbahnstrasse 4, Basel, CHE, 4051
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
38GF Score

Get the complete analysis for FRA:D8Y

Defensive Interval Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€77.06
Price
€50.54
GF Value